# A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT01808482** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Part A: 100 mg/mL GSK2618960
- **DRUG:** Part A: matching placebo
- **DRUG:** Part B: Dose of GSK2618960 decided from Part A
- **DRUG:** Part B: matching placebo
- **DRUG:** Part C: Dose of GSK2618960 decided from Part A and B

## Key facts

- **NCT ID:** NCT01808482
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03-13
- **Primary completion:** 2013-08-06
- **Final completion:** 2013-08-06
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** GSK confirmed misrepresentation of preclinical data that supported the rationale for GSK2618960 in MS. This decreased benefit assessment for MS
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01808482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01808482, "A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01808482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*